<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "http://dtd.nlm.nih.gov/publishing/2.0/journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="2.0" xml:lang="EN">
  <front>    <journal-meta>
      <journal-title>Journal of Clinical Medicine and Research</journal-title>
      <issn pub-type="epub">2141-2235</issn>      <publisher>
        <publisher-name>Academic Journals</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5897/JCMR2013.0242</article-id>
      <title-group>
        <article-title><![CDATA[Using of hemofiltercytological blood test to monitor the quality of patients radically operated on for colorectal cancer adjuvant chemotherapy]]></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
        		        	<name name-style="western">
	            <surname>A.</surname>
            <given-names>A. Chimitov</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>S.</surname>
            <given-names>Dhibi</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>N.</surname>
            <given-names>Hfeidh</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>A.</surname>
            <given-names>Elfeki</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>O.</surname>
            <given-names>Sergelen</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>G.</surname>
            <given-names>Ts. Dambaev</given-names>
	          </name>	
        		        	<name name-style="western">
	            <surname>T.</surname>
            <given-names>D. Khanhashanova</given-names>
	          </name>	
        	        </contrib>
      </contrib-group>
      <author-notes>
		<corresp id="cor1">* E-mail: <email xlink:type="simple">optimiste236@yahoo.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
      	<day>30</day>
        <month>06</month>
        <year>2014</year>
      </pub-date>
      <history>
      			<date date-type="received">
			<day>18</day>
			<month>06</month>
			<year>2014</year>
		</date>
						<date date-type="accepted">
			<day>18</day>
			<month>06</month>
			<year>2014</year>
		</date>
			  </history>
      <volume>6</volume>
      <issue>2</issue>
	  	  <fpage>11</fpage>
	  <lpage>15</lpage>
      <permissions>
		<license xlink:type="simple">
			<license-p>
			This is an open-access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
			</license-p>
		</license>
	  </permissions>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JCMR/article-abstract/1E95FC745450">
		This article is available from http://politicalwaffle.uk/journal/JCMR/article-abstract/1E95FC745450	  </self-uri>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JCMR/article-full-text-pdf/1E95FC745450">
		The full text article is available as a PDF file from http://politicalwaffle.uk/journal/JCMR/article-full-text-pdf/1E95FC745450	  </self-uri>
	  
      <abstract><![CDATA[Application of hemofiltercytological analysis shows its ample opportunities in assessment of polychemotherapy completeness and quality through the study of drug pathomorphosis. The objective of the study was development and studying of the clinical relevance of hemofiltercytological venous blood test as completeness and quality control of patients with colorectal cancer adjuvant chemotherapy. 35 of 39 tested cancer patients who underwent radical surgery for colorectal cancer of different localization, including cases of locally advanced stage had cancer cells in peripheral blood. Thus, the percentage of patients who had atypical cells in venous blood in postoperative period was 89.7. Adjuvant chemotherapy was offered to all 35 patients with diagnosed carcinemia and after their consent it was held in modes FOLFOX-4 and XELOX. Evaluation of anticancer drugs therapeutic action is traditionally carried out using the criteria of objective and subjective effects. The criterion of objective effect during chemotherapy of solid tumors is reduction of tumor and metastases and the criterion of subjective one is well-being of a patient. In addition, it is important to notice the highest drug resistance observed at rectum cancer, because there is a predominance of smaller stages I to II of drug pathomorphosis (9 to 7) over greater stages III-IV (7 to 1) among these cancer patients. Consequently, hemofiltercytological blood test provides a real opportunity to assess the effect of polychemotherapy and to solve the problem of chemotherapeutic treatment courses number necessary to stabilize the cancer process.

	 

	Key words: Calibrated filter, hemofiltercytological blood test, carcinemia, microscreening.]]></abstract>
    </article-meta>
  </front>
      <body/>
    <back>
		<ref-list>
			<title>References</title>
						<ref id="ref1">
				<label>1</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Perevodchikova NI (2011). Guidelines for chemotherapy of tumoral diseases, 3rd ed. Moscow: Prakticheskaya Meditsina. P 512.]]>
				</mixed-citation>
			</ref>
						<ref id="ref2">
				<label>2</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Haller DG (2001). New approaches to adjuvant therapy for colorectal cancer. 3rd International Conference on Perspectives in Colorectal Cancer, a consensus meeting, Dublin, Ireland. pp. 107-111.]]>
				</mixed-citation>
			</ref>
						<ref id="ref3">
				<label>3</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1995). Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122(5):321-326.
				]]>
				</mixed-citation>
			</ref>
						<ref id="ref4">
				<label>4</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Perevodchikova NI, Reutova EV (2001). Chemotherapy for colorectal cancer. Rus. Med. Zhurn. 9(22):968-973.]]>
				</mixed-citation>
			</ref>
						<ref id="ref5">
				<label>5</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Vogel I, Soeth E, Ruder C. Moertel CG, Fleming TR, DonaldJS (2000). Disseminated tumor cells in the blood and/or bone of patients with colorectal carcinoma are an independent prognostic factor. Ann. Oncol. 11(4):43.]]>
				</mixed-citation>
			</ref>
					</ref-list>
	</back>
    </article>